Table 2. PSA comparison of low-dose PQ informed by G6PD testing (100% access) to low-dose PQ used without G6PD testing, assuming 100% adherence to the low-dose PQ regiment.
| G6PDd prevalence | Sex | Median change in no. SH events per 10,000 patients (10th– 90th percentile) | Median change in no. recurrences per 10,000 patients (10th– 90th percentile) | Percent of simulations (n = 10,000) | |||
|---|---|---|---|---|---|---|---|
| More SH; more recurrences | More SH; fewer recurrences | Fewer SH; more recurrences | Fewer SH; fewer recurrences | ||||
| 1% | Male | -6.4 (-20.4 –-1.3) | 64.4 (41.9–95.3) | 0.0 | 0.0 | 100.0 | 0.0 |
| Female | -0.7 (-5.5 –-0.1) | 58.1 (37.6–86.5) | 0.0 | 0.0 | 100.0 | 0.0 | |
| 5% | Male | -39.3 (-71.2 –-19.1) | 96.0 (64.2–139.7) | 0.0 | 0.0 | 100.0 | 0.0 |
| Female | -7.0 (-22.0 –-1.5) | 65.4 (42.5–96.6) | 0.0 | 0.0 | 100.0 | 0.0 | |
| 10% | Male | -81.4 (-128.8 –-47.1) | 136.8 (92.3–194.9) | 0.0 | 0.0 | 100.0 | 0.0 |
| Female | -18.5 (-40.9 –-6.9) | 76.8 (50.3–112.9) | 0.0 | 0.0 | 100.0 | 0.0 | |
SH: severe haemolysis